NCT03138733: A reported trial by Basilea Pharmaceutica
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03138733 |
|---|---|
| Title | A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 26, 2018 |
| Completion date | March 11, 2022 |
| Required reporting date | March 11, 2023, midnight |
| Actual reporting date | March 6, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |